Organon & Co.

OGN

Healthcare Drug Manufacturers General

Organon & Co.’s revenue for fiscal 2025 (year ended December 2025) was $6.2 billion, down 2.92% from fiscal 2024.

Revenue
−1.75%
EPS
+1.64%
Free cash flow
+118.8%
Total debt
−3.10%

Quarter to September 2026, against a year earlier

13.87 0.08 +0.58%
Market cap
$3.6B
P/E
17.3×
Fwd P/E
6.2×
Dividend yield
0.58%
F-score
5/9
ROIC
6.26%
Net debt / EBITDA
5.6×
Dividend safety
45/100
Dec '25 Dec '24 Dec '23 Dec '22 Dec '21 Dec '20 Dec '19 Dec '18 Dec '17
Piotroski F-Score
5 5 4 5 4 — — — —
P/E ratio
9.96 4.45 3.66 7.80 5.71 4.54 4.54 4.54 4.54
Altman Z-Score
1.09 1.27 1.26 1.51 1.52 — — — —
P/S ratio
0.30 0.60 0.60 1.16 1.22 1.35 1.35 1.35 1.35
Altman Z″-Score (non-manufacturers)
1.78 1.81 1.68 1.64 1.41 — — — —
P/FCF ratio
4.48 5.78 8.29 13.09 3.91 3.39 3.39 3.39 3.39
Beneish M-Score
(2.68) (2.62) (2.21) (2.40) (3.56) (2.93) — — —
P/Operating CF
13.20 9.83 9.46 26.71 164.26 6.48 6.48 6.48 6.48
Dividend Safety Score
45 — — — — — — — —
P/B ratio
2.47 8.13 0.00 0.00 0.00 1.79 1.79 1.79 1.79
EV/Sales
1.60 1.88 1.89 2.48 2.56 1.49 1.49 1.49 1.49
EV/EBITDA
6.92 7.24 7.92 8.61 8.38 3.75 3.75 3.75 3.75
EV/FCF
23.93 18.16 26.10 28.15 8.16 3.76 3.76 3.76 3.76
Current Ratio
1.82 1.60 1.54 1.56 1.45 1.33 2.95 2.40 —
Net Debt/EBITDA
5.62 4.94 5.40 4.61 4.69 0.01 (0.05) (0.02) 0.00
Debt/Equity
11.49 18.81 (125.14) (9.99) (6.06) 0.01 0.02 0.00 —
ROE
30.56% 429.85% (212.68%) (76.42%) 67.92% 34.50% 48.09% 32.18% 0.00%
ROA
1.44% 6.87% 8.89% 8.48% 13.00% 20.91% 61.02% 0.00% 0.00%
ROIC
5.84% 9.90% 9.82% 13.41% 16.25% 31.74% 33.80% 0.00% —
Return on Tangible Assets
5.73% 30.88% 36.89% 37.63% 63.25% 115.02% 97.69% 76.35% 0.00%
Average Days of Receivables
78.16 77.41 101.64 87.20 80.02 58.00 69.18 59.92 0.00
Earnings Yield
10.04% 22.45% 27.33% 12.83% 17.50% 22.04% 22.04% 22.04% 22.04%
Free Cash Flow Yield
22.30% 17.29% 12.07% 7.64% 25.58% 29.46% 29.46% 29.46% 29.46%
Free Cash Flow per Share
1.60 2.58 2.14 2.15 7.03 8.02 11.57 14.30 13.51
Book value per Share
2.90 1.84 (0.27) (3.51) (5.95) 21.64 27.75 0.00 0.00
Free Cash Flow
415.00 663.00 547.00 545.00 1,783.00 2,034.00 2,932.00 3,618.00 3,419.00
EV/EBIT
12.05 8.76 9.40 9.77 9.00 4.01 4.01 4.01 4.01
Other line items

Show all line items

Columns are period end dates · fundamentals updated 5 Nov 2026